Business
Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab
BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of its open-label study in patients with non-active secondary progressive multiple sclerosis (na-SPMS) in Neurology Neuroimmunology & Neuroinflammation, a prestigious journal of the American Academy of Neurology. The publication, titled “Na
About this update from Tiziana Life Sciences Ltd
[{"type":"image","alt":"Tiziana Life Sciences Ltd.","displaySize":"","headline":null,"caption":"Tiziana Life Sciences Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":264,"height":60,"url":"https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3k64r3yQgq2ENSiAhwIMCA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk1O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/08f5d705b5df39888a6496fd7522f947","width":264,"height":60}},"lazy":false},{"type":"text","content":"BOSTON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the peer-reviewed publication of its open-label study in patients with non-active secondary progressive multiple sclerosis (na-SPMS) in Neurology Neuroimmunology & Neuroinflammation, a prestigious journal of the American Academy of Neurology.","length":476,"tagName":"p"},{"type":"text","content":"The publication, titled “Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients with Non-active Secondary Progressive Multiple Sclerosis,” details the comprehensive positive results previously announced by the Company on May 6, 2025. This marks the first study to integrate TSPO-PET imaging, proteomics, and clinical assessments in na-SPMS, highlighting nasal foralumab's novel mechanism in addressing progression independent of relapse activity (PIRA)—a critical unmet need in multiple sclerosis (MS) treatment.","length":546,"tagName":"p"},{"type":"text","content":"Key Study Highlights:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Ten patients with na-SPMS, progressing despite prior B-cell therapies, received nasal foralumab for at least six months.","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"No serious or severe treatment-related adverse events occurred.","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"All patients showed stabilization of Expanded Disability Status Scale (EDSS) scores; three of four treated for 12 months demonstrated improvement.","length":146,"tagName":"p"}]},{"val":[{"type":"text","content":"Fatigue improved in six out of ten patients, as measured by ...